Catalent Pharma Solutions and Cevec Pharmaceuticals have entered a commercial cell line sales agreement for recombinant human alpha-1 antitrypsin (hAAT). The companies have also signed a joint development and marketing agreement combining their respective technologies, Cevec’s CAP cell line, a high performance protein expression platform and Catalent’s GPEx technology, a gene-insertion method providing single-copy gene integration at multiple genomic locations in dividing cells.   Cevec, a devel...